El interés en corto de Nippon Steel da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Nippon Steel. Los datos de interés en corto se actualizan cada dos semanas.

Nippon Steel (OTC:NPSCY) Bolsa, Informe de interés en corto

Nippon Steel Corporation, or NS, is the largest steel producer in Japan and one of the top five producers globally. NS supplies steel products such as steel sheets, steel plates, pipes, tubes, bars, wire rods, and stainless steels. It is mainly exposed to the auto, construction, and energy sectors. Steelmaking accounts for around 85%-90% of its revenue, while the remainder stems from engineering and construction, chemicals, new materials, and system solutions. Around 35%-40% of its revenue is from exports.

News

Commodities

Movers

Media

Trading Ideas

NPSCY

Joe Biden bloquea la adquisición de U.S. Steel por Nippon Steel, citando preocupaciones de seguridad nacional y defensa de la industria local.

Biden bloquea la compra de U.S. Steel por Nippon Steel: Seguridad nacional en juego

NIPPON STEEL CORP S/ADR by Nippon Steel Corporation

Nippon Steel Corp

JP Morgan analyst Daniel Politzer initiates coverage on Wyndham Hotels &amp; Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WH#NYSE">WH</a>) with a Overweight rating and announces Price Target of $101.

Price Target

Initiation

Analyst Ratings

JP Morgan Initiates Coverage On Wyndham Hotels & Resorts with Overweight Rating, Announces Price Target of $101

JP Morgan analyst Daniel Politzer initiates coverage on Sunstone Hotel Invts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHO#NYSE">SHO</a>) with a Underweight rating and announces Price Target of $8.

JP Morgan Initiates Coverage On Sunstone Hotel Invts with Underweight Rating, Announces Price Target of $8

BMO Capital analyst John McNulty downgrades Dow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>) from Market Perform to Underperform and lowers the price target from $29 to $22.

Downgrades

BMO Capital Downgrades Dow to Underperform, Lowers Price Target to $22

Siyata Mobile Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/SYTA#NASDAQ">SYTA</a>, SYTAW)) ("Siyata" or the "Company"), a global developer and vendor of mission-critical Push-to-Talk over Cellular (PoC) handsets and accessories, today announced that Core Gaming, a rising innovator in AI-driven creative technologies, who it recently signed a definitive merger agreement with, is experiencing continued momentum with its innovative AI COMIC app.
&nbsp;
In less than one year, combined user numbers of AI COMIC in Japan and South Korea have jumped from 2,500 to over 32,000, a 13x increase, while those countries' share of total global users rose from 4.12% to 14.38%.
"AI COMIC's breakout success in Japan and South Korea is a powerful validation of our strategic vision," said Aitan Zacharin, CEO of Core Gaming. "Return on investment in the region has more than tripled, driven by targeted localization efforts such as a language-optimized user interface. Just as important, the virality we are seeing through widely used platforms like TikTok and Facebook underscores how deeply users are engaging with our product."
Launched to broad interest, AI COMIC blends next-gen AI capabilities with a uniquely immersive user experience. The app empowers users to transform everyday visuals into vivid anime-style content through features such as AI-generated video, personalized avatars, manga scene recreation, time-lapse aging and realistic face swaps.
Zacharin continued, "AI COMIC runs on a robust technological foundation built on our proprietary Compute Pool System, multimodal generative AI models and a scalable cloud orchestration architecture that is redefining content creation and distribution. Importantly, our goal is not just to build apps. We are building a robust, scalable AI infrastructure designed to power creative expression on a global scale. AI COMIC is only the beginning."
Technology Platform: A Breakthrough AI Engine
While AI COMIC continues to attract headlines and users, the underlying technology is the true differentiator. To support rapid growth and creative demand, Core Gaming built a smart, cloud- based infrastructure that delivers scalable AI performance while keeping costs efficient. This foundation enables the platform to streamline game asset creation—from automated scene and character generation to fast, high-quality animations and ad creatives—helping content teams iterate faster and bring ideas to life with minimal effort.
Core Gaming's AI infrastructure is designed around three core pillars:
<ul>
<li>Compute Pool System (CPS) is a dynamic AI task distribution engine that allocates computational resources across workloads in real time. CPS ensures optimal throughput for video generation, avatar rendering and real-time user interactions—without overprovisioning infrastructure. &nbsp;</li>
<li>Multimodal Generative Models that process and synthesize visual, text and audio inputs simultaneously, enabling complex creative outputs such as dialogue-driven animation, mood-based styling, and high-resolution content generation tailored to the user's intent. &nbsp;</li>
<li>Proprietary BigP Backend and Cloud Orchestration serves as the orchestration layer for model training, inference pipelines and content delivery. Integrated with a globally distributed cloud framework, it scales elastically to meet creative surges whether from new user spikes or major feature rollouts.</li>
</ul>

SYTA

Siyata's Merger Partner Core Gaming Sees AI Comic App Users Surge 13x in Japan and South Korea

JP Morgan analyst Daniel Politzer initiates coverage on Ryman Hospitality Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RHP#NYSE">RHP</a>) with a Overweight rating and announces Price Target of $117.

JP Morgan Initiates Coverage On Ryman Hospitality Props with Overweight Rating, Announces Price Target of $117

Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) on Saturday announced detailed results from the ACHIEVE-1 Phase 3 trial of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control with <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">diet and exercise alone</a>.
The company released its topline data <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44871681/lillys-diabetes-pill-clears-major-trial-analyst-points-to-global-potential" rel="noreferrer noopener">from the trial in April</a>.
At 40 weeks, all three doses (3 mg, 12 mg, 36 mg) of orforglipron achieved the primary endpoint of superior A1C reduction.
Also Read: <a href="https://www.benzinga.com/analyst-stock-ratings/downgrades/25/06/46003836/eli-lillys-1-3-billion-verve-deal-signals-confidence-in-gene-editing-space-analyst" target="_blank" rel="noreferrer noopener">Eli Lilly&#8217;s $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst</a>
In addition, the 12 mg and 36 mg doses showed clinically meaningful and statistically significant reductions in <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n46041936/lillys-oral-glp-1-orforglipron-showed-compelling-efficacy-and-a-safety-profile-consistent-with-inj" rel="noreferrer noopener">body weight vs. placebo</a>.
In the study, orforglipron met the primary endpoint of superior A1C reduction compared to placebo at 40 weeks, lowering A1C by 1.3% to 1.6% from a baseline of 8.0% for the efficacy estimand.
In key secondary endpoints, up to 76.2% of participants taking orforglipron achieved the ADA treatment target A1C of &lt;7%, 66.0% achieved an A1C of ≤6.5%, and 25.8% achieved &lt;5.7%, defined as a normal A1C value.
Improvements in A1C were observed as early as four weeks and were accompanied by similar reductions in fasting serum glucose.
In another key secondary endpoint, participants taking the highest dose of orforglipron lost an average of 16.0 lbs (7.9%). 
While participants in ACHIEVE-1 did not appear to reach a weight plateau, longer-duration trials, such as the ATTAIN trials, will provide a comprehensive evaluation of the safety and efficacy of orforglipron for obesity.
While the tolerability profile was in line with the incretin class, William Blair highlights that at the highest dose, nausea, vomiting, and constipation did not appear to subside over time, in contrast with its peptide GLP-1 receptor agonist counterparts.
&#8220;We are less bullish about the prospects of orforglipron in this setting for two reasons: early plateauing and persistent side effects,&#8221; said analyst Andy Hsieh.
<h2 class="wp-block-heading">Once-Weekly Insulin Efsitora</h2>
In addition to the orforglipron data, Eli Lilly also shared promising results for its investigational once-weekly insulin, efsitora.
On Sunday, Eli Lilly announced detailed results from QWINT-1, QWINT-3, and QWINT-4 Phase 3 trials evaluating the safety and efficacy of investigational once-weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes who used insulin for the first time, previously used daily basal insulin, and previously used daily basal insulin <a href="https://www.benzinga.com/pressreleases/25/06/n46043947/lillys-once-weekly-insulin-efsitora-alfa-demonstrated-a1c-reduction-and-a-safety-profile-consisten" target="_blank" rel="noreferrer noopener">and mealtime insulin, respectively</a>.
Eli Lilly released topline results from the QWINT-1 and QWINT-3 trials <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40731728/eli-lillys-once-weekly-insulin-shows-non-inferior-blood-sugar-reduction-vs-frequently-used-daily-" rel="noreferrer noopener">in September 2024</a>.
In each trial, once-weekly efsitora met the primary endpoint of non-inferior A1C reduction compared to daily basal insulin.
In QWINT-1, efsitora reduced A1C by 1.31% compared to 1.27% for insulin glargine at week 52 for the efficacy estimand.
In the trial, efsitora was titrated to four fixed doses at four-week intervals, as needed for blood glucose control.
In QWINT-3, efsitora reduced A1C by 0.86% compared to 0.75% for insulin degludec at week 26 for the efficacy estimand. In QWINT-4, efsitora reduced A1C by 1.07% compared to 1.07% for insulin glargine.
Lilly plans to submit&nbsp;efsitora for adults with type 2 diabetes to global regulatory agencies by the end of this year.
In QWINT-1, efsitora resulted in approximately 40% fewer hypoglycemic events compared to insulin glargine, with estimated combined rates of severe or clinically significant hypoglycemic events per patient-year of exposure of 0.50 with efsitora vs. 0.88 with insulin glargine at 52 weeks. In QWINT-3, these rates were 0.84 with efsitora vs. 0.74 with insulin degludec at 78 weeks.
In QWINT-4, estimated combined rates of severe or clinically significant hypoglycemic events per patient-year of exposure were 6.6 with&nbsp;efsitora vs. 5.9 with insulin glargine at 26 weeks.
Across the three trials, efsitora demonstrated an overall safety profile similar to two of the most commonly used daily basal insulin therapies for type 2 diabetes.
Price Action: LLY stock is trading lower by 0.19% to $761.25 premarket at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/46036868/obesity-drugs-help-with-weight-loss-but-are-adding-fat-elsewhere" target="_blank" rel="noreferrer noopener">Obesity Drugs Help With Weight Loss But Are Adding Fat Elsewhere</a></li>
</ul>
Image via Shutterstock

Biotech

Large Cap

Health Care

General

Eli Lilly's Investigational Oral Pill Shows Weight Loss Benefits With Lingering Side Effect Concerns

Guardforce AI Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GFAI#NASDAQ">GFAI</a>) on Monday <a target="_blank" href="https://www.benzinga.com/topic/ai" rel="noreferrer noopener">announced that its</a> subsidiary, Guardforce Cash Solutions Security (Thailand) Company Limited (GFCS), has won a three-year renewal with Government Savings Bank (GSB).
GSB one of Thailand&#8217;s state-owned banks adn the renewal deal is effective from June 1, 2025, through May 31, 2028.
This fourth consecutive renewal represents a decade-long partnership between the company and GSB.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/12/42314074/exclusive-guardforce-ai-taps-librum-technologies-to-boost-ai-agent-capabilities" rel="noreferrer noopener">Guardforce AI Taps Librum Technologies To Boost AI Agent Capabilities</a>
Under the renewed agreement, GFCS will continue to provide secure and efficient cash-in-transit and maintenance services for GSB&#8217;s ATM network across Thailand&#8217;s upcountry regions, which covers most of the company&#8217;s ATM services currently handled.
With this renewal, Guardforce AI will secure stable and predictable revenue streams over the next three years, providing the company with a solid financial foundation to invest in innovation and expand its AI-driven solutions, the company said.
In January, GFCS <a target="_blank" href="https://www.benzinga.com/news/25/01/43262471/exclusive-guardforce-ai-expands-partnership-with-government-savings-bank-in-thailand" rel="noreferrer noopener">renewed key contracts</a> with its long-time customer GSB in Thailand. Under two three-year multi-million-dollar contracts, GFCS continued to deliver cash center operations and secure logistics services for coins.
Price Action: GFAI stock closed lower by 3.33% at $1.16 Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/06/46040754/amazons-powerful-aws-custom-chip-to-get-an-upgrade-why-is-it-important" target="_blank" rel="noreferrer noopener">Amazon&#8217;s Powerful AWS Custom Chip To Get An Upgrade &#8211; Why Is It Important?</a></li>
</ul>
Photo via Company

Market-Moving Exclusives

Exclusives

GFAI

GFAIW

EXCLUSIVE: Guardforce AI Renews 3-Year Deal With Thailand's Government Savings Bank

EXCLUSIVE: Guardforce AI Tells Benzinga 'Ensuring Stable Revenue Streams to Drive Future AI Innovations'

EXCLUSIVE: Guardforce AI Tells Benzinga Co. Strengthens Decade-Long Client Relationships By Securing Long-Term Contract With Government Savings Bank

WIIM

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Hims & Hers Health shares are trading lower after Novo Nordisk reportedly terminated its collaboration with the company.

CARM

OCGN

Carisma Therapeutics And Ocugen Subsidiary, OrthoCellix, Enter All-Stock Merger Agreement; Carisma Will Issue To The Pre-Merger OrthoCellix Stockholder Shares Of Carisma Common Stock As Merger Consideration In Exchange For The Cancellation Of Shares Of Capital Stock Of OrthoCellix

Fractyl Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GUTS#NASDAQ">GUTS</a>) (the Company or Fractyl), a metabolic therapeutics company focused on pattern-breaking approaches that treat root causes of obesity and type 2 diabetes (T2D), today announced positive 3-month data from the REVEAL-1 Cohort of its ongoing REMAIN-1 pivotal study. These findings suggest Revita may help people stay at their target weight or lose additional weight, even after discontinuing GLP-1 drugs, offering a potential path to durable, drug-free weight maintenance.
3-Month Outcomes in REVEAL-1 Show Strong Early Signal for Durable Weight Maintenance REVEAL-1 is the open-label cohort within the ongoing REMAIN-1 pivotal study, designed to evaluate the safety, tolerability, and early efficacy signals of Revita in individuals with obesity who have lost at least 15% of their total body weight on a recently discontinued GLP-1 therapy. This cohort serves as an early clinical window into Revita's potential to support durable weight maintenance following GLP-1 discontinuation, a period of time when patients are typically vulnerable to rapid weight regain. Participants undergo a single Revita procedure in an open-label setting and receive structured diet and lifestyle support consistent with the ongoing randomized, controlled, REMAIN-1 clinical study. The insights from REVEAL-1 are intended to inform and complement data from the randomized Midpoint and Pivotal Cohorts in REMAIN-1.
To date, 22 participants have been treated in the REVEAL-1 Cohort, with 3-month follow-up data available for 13 individuals. The profile of the REVEAL-1 Cohort closely mirrors that of the REMAIN-1 Midpoint and Pivotal Cohorts, with an average age of 49 and a gender distribution of 11 women and 2 men. All participants had previously been treated with a GLP-1 therapy for durations ranging from approximately 5 months to 3 years, with a median total body weight (TBW) loss of 20.9% while on therapy. Fifteen percent of participants had pre-diabetes at baseline.
<ul>
<li>At 3 months, 12 of 13 participants either lost or maintained their weight after GLP-1 discontinuation and a single Revita procedure. Notably, 6 of 13 experienced further weight loss.</li>
<li>Median weight remained stable through 3 months (TBW change of 0.46% / ~ 1 pound was within the margin of error for daily weight measurement), compared to the typical 5-6% (10–15 pounds) rebound seen in clinical studies such as SURMOUNT-41 2. Only one participant experienced weight regain similar to that seen after tirzepatide withdrawal.</li>
<li>Early signs also point to excellent weight stability following Revita procedure, with essentially no weight change between 1 and 3 months (median weight gain at 1 month: 0.43% and 3 months: 0.46%).</li>
<li>Consistent with prior studies of Revita, the procedure was well tolerated, with no unanticipated or serious adverse effects. No new safety concerns were observed.</li>
</ul>

GUTS

Fractyl Reports Most Patients Maintained or Lost Weight 3 Months After Stopping GLP-1 Drugs

Novo Nordisk Terminates Collaboration With Hims & Hers Health, Direct Access To Wegovy Will No Longer Be Available To Hims & Hers Health, Inc. Via Novocare Pharmacy

JP Morgan analyst Daniel Politzer initiates coverage on Park Hotels &amp; Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PK#NYSE">PK</a>) with a Underweight rating and announces Price Target of $10.

JP Morgan Initiates Coverage On Park Hotels & Resorts with Underweight Rating, Announces Price Target of $10

Baird analyst David Tarantino maintains Darden Restaurants (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) with a Neutral and raises the price target from $218 to $230.

Baird Maintains Neutral on Darden Restaurants, Raises Price Target to $230

<figure class="wp-block-image aligncenter size-full"><img loading="lazy" decoding="async" width="896" height="504" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23064915/Syringes.jpg" alt="" class="wp-image-14732" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23064915/Syringes.jpg 896w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23064915/Syringes-300x169.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23064915/Syringes-768x432.jpg 768w" sizes="(max-width: 896px) 100vw, 896px" /></figure>
Two Biotechs Poised For Big Moves On Monday (Sana Biotechnology &#x7C; Lineage Cell Therapeutics)
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h3 class="wp-block-heading">1&#xFE0F;&#x20E3; Sana Biotechnology</h3>
Sana Biotechnology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANA#NASDAQ">SANA</a>)
Catalyst: Invited six-month clinical update — ADA Scientific Sessions, Monday @ 10:30 a.m. CT <a href="https://ir.sana.com/news-releases/news-release-details/sana-biotechnology-announces-invited-oral-presentation-85th?utm_source=chatgpt.com" target="_blank" rel="noreferrer noopener">ir.sana.com</a><a href="https://www.globenewswire.com/news-release/2025/06/09/3096183/0/en/Sana-Biotechnology-Announces-Invited-Oral-Presentation-at-the-85th-Annual-American-Diabetes-Association-Scientific-Sessions.html?utm_source=chatgpt.com" target="_blank" rel="noreferrer noopener">globenewswire.com</a>
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<thead>
<tr>
<th>What we'll hear</th>
<th>Why it matters</th>
</tr>
</thead>
<tbody>
<tr>
<td>First-in-human data on UP421, a hypoimmune‐modified islet-cell therapy for Type 1 diabetes</td>
<td>• One treated patient is six months insulin- &amp; immunosuppression-free. • If replicated, UP421 could leapfrog donor-islet transplants, the current gold standard that still requires lifelong immunosuppression.</td>
</tr>
<tr>
<td>Safety &amp; durability profile through 180 days</td>
<td>• The ADA crowd is data‐driven: low adverse events and durable C-peptide levels would de-risk the platform.</td>
</tr>
<tr>
<td>Expansion path (multi-patient cohort)</td>
<td>• Positive signals open the door to "breakthrough" or RMAT dialogue with FDA, accelerating timelines.</td>
</tr>
</tbody>
</table>
</figure>
Why the stock could pop Monday
<ul class="wp-block-list">
<li>Audience effect: the ADA meeting pulls in ~11-12 k registrants; roughly 3–4 k are adult endocrinologists who influence treatment paradigms and often trade or recommend names they've just seen. <a href="https://www.breakthrought1d.org/news-and-updates/adas-85th-scientific-sessions/?utm_source=chatgpt.com" target="_blank" rel="noreferrer noopener">breakthrought1d.org</a></li>
<li>Scarcity value: no other public company has shown insulin independence without immunosuppression.</li>
<li>Float dynamics: SANA's free float is only ~24 % of shares outstanding; a modest uptick in buy-interest can move the tape quickly.</li>
</ul>
Watch-for: If the single-patient success extends to the next two patients in cohort B, look for sell-side upgrades and chatter about a pivotal trial design in H2-25.
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h3 class="wp-block-heading">2&#xFE0F;&#x20E3; Lineage Cell Therapeutics</h3>
Lineage Cell Therapeutics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LCTX#NYSE">LCTX</a>)
Catalyst window: Genentech PR "within weeks" + 36-month OpRegen&#xAE; read-out at CTS-2025 (June 27) <a href="https://www.businesswire.com/news/home/20250512395886/en/RG6501-OpRegen-Phase-12a-Clinical-Study-36-Month-Results-to-Be-Featured-at-Clinical-Trials-at-the-Summit-2025?utm_source=chatgpt.com" target="_blank" rel="noreferrer noopener">businesswire.com</a><a href="https://www.businesswire.com/news/home/20250605204221/en/Lineage-Cell-Therapeutics-Announces-Updates-to-the-3rd-Annual-Spinal-Cord-Injury-Investor-Symposium?utm_source=chatgpt.com" target="_blank" rel="noreferrer noopener">businesswire.com</a><a href="https://www.modernretina.com/view/lineage-to-announce-data-from-phase-1-2a-study-on-use-of-rg6501?utm_source=chatgpt.com" target="_blank" rel="noreferrer noopener">modernretina.com</a>
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<thead>
<tr>
<th>What could hit</th>
<th>Price-sensitive angle</th>
</tr>
</thead>
<tbody>
<tr>
<td>Roche Holding AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) subsidiary Genentech/LCTX services-agreement milestones or data-share PR</td>
<td>• Prior Genentech press releases on OpRegen have triggered double-digit one-day moves in LCTX.</td>
</tr>
<tr>
<td>36-month functional vision data (phase 2a, GA secondary to AMD)</td>
<td>• If BCVA gains remain ≥7 letters and lesion growth stays slowed, analysts will start modelling blockbuster-size royalties.</td>
</tr>
<tr>
<td>Potential partner opt-in for spinal cord (SCIIS meeting)</td>
<td>• Separately, Lineage tees-up a June 27 investor symposium on spinal cord injury – any strategic partner news adds another risk-on spark.</td>
</tr>
</tbody>
</table>
</figure>
Why Monday could be the start of a new leg
<ul class="wp-block-list">
<li>Pattern set-up: the stock has been basing in the $1.60–1.80 zone; traders remember the May 2024 Genentech PR that drove a 40 % gap.</li>
<li>Valuation gap: LCTX trades at &lt; 3× 2026e OpRegen royalty sales versus cell-therapy peers at 8–10×.</li>
<li>Short-term IV low: front-month at-the-money calls imply a ±12 % move by July — well under the 20–30 % jumps we saw on the last three data bursts.</li>
</ul>
Watch-for: A Monday-morning 8-K or Genentech newsroom post; if nothing drops, option premiums may leak until later in the week — keep a trading tranche nimble.
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h3 class="wp-block-heading">Tactical takeaways</h3>
<ol class="wp-block-list">
<li>SANA: momentum play into the ADA deck. Small float + novel cure angle = potential volatility.</li>
<li>LCTX: event-driven swing; even a "PR-then-data" one-two punch could squeeze shorts.</li>
<li>Risk management: both names are clinical-stage — size positions modestly, use stops, and consider call-spreads to bound downside.</li>
</ol>
<hr class="wp-block-separator has-alpha-channel-opacity" />
Bottom line: Monday's calendar lines up two asymmetric biotech shots: If Sana's six-month data look anything like the first patient's, endocrinologists will be talking — and buying — before lunch. If Lineage's big-pharma partner steps back into the headlines, we could see the May-style pop all over again.
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h3 class="wp-block-heading">Our positions in both stocks</h3>
Portfolio Armor Substack subscribers and I are long SANA and LCTX via options. I wrote about SANA <a href="https://www.benzinga.com/general/biotech/25/05/45498697/the-end-of-the-diabetes-industry-this-small-cap-could-upend-the-business-models-of-pharma-giants">here</a>.
<figure class="wp-block-image size-full"><a href="https://portfolioarmor.substack.com/p/the-end-of-the-diabetes-industry"><img loading="lazy" decoding="async" width="828" height="812" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23050427/SANA.jpg" alt="" class="wp-image-14724" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23050427/SANA.jpg 828w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23050427/SANA-300x294.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23050427/SANA-768x753.jpg 768w" sizes="(max-width: 828px) 100vw, 828px" /></a></figure>
And I first wrote about LCTX <a href="https://portfolioarmor.substack.com/p/trade-alert-biotech-lotto-ticket">last Friday</a>. 
<figure class="wp-block-image size-full"><a href="https://portfolioarmor.substack.com/p/trade-alert-biotech-lotto-ticket"><img loading="lazy" decoding="async" width="833" height="733" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23050717/LCTX.jpg" alt="" class="wp-image-14725" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23050717/LCTX.jpg 833w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23050717/LCTX-300x264.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23050717/LCTX-768x676.jpg 768w" sizes="(max-width: 833px) 100vw, 833px" /></a></figure>
We plan on selling half of our positions into a strong upward move to lock in profits. 
If you would like a heads up when we place our next trade, feel free to subscribe to the Portfolio Armor Substack below. 
<figure class="wp-block-image aligncenter size-full"><a href="https://portfolioarmor.substack.com/"><img loading="lazy" decoding="async" width="581" height="372" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23050929/Widget-2-1.jpg" alt="" class="wp-image-14726" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23050929/Widget-2-1.jpg 581w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23050929/Widget-2-1-300x192.jpg 300w" sizes="(max-width: 581px) 100vw, 581px" /></a></figure>
And if you want to limit your downside risk, in light of the conflict in the Mideast, consider <a href="https://apps.apple.com/us/app/portfolio-armor/id394951144">the Portfolio Armor iPhone app</a> or <a href="https://apps.apple.com/us/app/portfolio-armor/id394951144">website</a>. Both will help you scan for the optimal hedge given your risk tolerance and time frame. 
<figure class="wp-block-image aligncenter size-large"><a href="https://apps.apple.com/us/app/portfolio-armor/id394951144"><img loading="lazy" decoding="async" width="1024" height="683" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23051320/PA-JPEG-1-2-1024x683.jpeg" alt="" class="wp-image-14727" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23051320/PA-JPEG-1-2-1024x683.jpeg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23051320/PA-JPEG-1-2-300x200.jpeg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23051320/PA-JPEG-1-2-768x512.jpeg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23051320/PA-JPEG-1-2.jpeg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>

Long Ideas

Options

Opinion

LCTX

RHHBY

SANA

Two Biotech Stocks Poised For Big Moves On Monday

CRCL: 10% &#x7C; <a href="https://www.benzinga.com//node/46048835">Fiserv Plans To Launch Fiserv Digital Asset Platform, Including New Stablecoin FIUSD; FIUSD Expects To Use Stablecoin Infrastructure From Paxos And Circle Internet Group</a>
&nbsp;
TSLA: 1.75% &#x7C; <a href="https://www.benzinga.com//node/46048103">Tesla's Robotaxi Rollout Sparks Expansion Buzz: Elon Musk's Company Says FSD 'Can Be Deployed Anywhere' After Austin Launch</a>
&nbsp;
SQNS: 64% &#x7C; <a href="https://www.benzinga.com//node/46048013">Sequans Unveils $384M Strategic Investment To Launch Bitcoin Treasury Initiative While Advancing 5G And IoT Core Mission</a>

CRCL

SQNS

TSLA

Market-Moving News for June 23rd

Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) today announced new data from an indirect treatment comparison (ITC) that showed consistent and sustained disease control with IMAAVY&#x2122; (nipocalimab-aahu) versus other approved FcRn blockers in adults with generalized myasthenia gravis (gMG). These data, featured at the European Academy of Neurology (EAN) 2025 Congress in Helsinki, Finland, are among the 11 abstracts Johnson &amp; Johnson&nbsp;is presenting.
&nbsp;
Based on the ITC, which included the pivotal Phase 3 Vivacity-MG3 study data, IMAAVY showed comparable onset of symptom relief at Week 1 and showed consistent and sustained disease control with greater or statistically significant improvement of MG-ADLa scores versus the published Phase 3 data of other marketed FcRn blockers at several timepoints up to 24 weeksb of treatment.1 Results were consistent across multiple ITC methodsc.
<ul>
<li>Population-adjusted&nbsp;ITCs without a common control exhibited significantly greater mean improvements in MG-ADL scores favoring IMAAVY over other FcRn blockers, at Weeks 8-24d versus one comparator and at Weeks 10-14d versus another comparator.1</li>
<li>In placebo-adjusted&nbsp;ITCs, IMAAVY was associated with numerically greater efficacy versus one treatment comparator at Weeks 8e and 18-24e and versus another at Weeks 10-14e, with statistical significance at Weeks 10f and 12f</li>
</ul>

Johnson & Johnson Reports Data Showing IMAAVY Controls Myasthenia Gravis Symptoms Better Than Rivals

Baird analyst Rob Oliver downgrades Couchbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BASE#NASDAQ">BASE</a>) from Outperform to Neutral and raises the price target from $22 to $25.

BASE

Baird Downgrades Couchbase to Neutral, Raises Price Target to $25

CorMedix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announces an update related to its Large Dialysis Organization (LDO) customer and planned implementation in the second half of 2025.
CorMedix's LDO customer has commenced ordering and will begin the implementation of DefenCath in its patients. Implementation will initially target at least 50% more patients than previously communicated, with the opportunity for further expansion. In connection with this expanded utilization, CorMedix has amended its existing agreement with the LDO customer to reflect the anticipated increased use of product. CorMedix expects a modest revenue contribution in June, with growth expected over the back half of 2025.
As a result of this new customer implementation and other positive business developments, CorMedix is increasing its second quarter net sales guidance from the previously communicated $31mm to a range of $35mm to $40mm.
"I am excited to announce that our LDO customer is moving forward with the implementation of DefenCath. Their implementation of our product will provide access to DefenCath for thousands of adult patients at risk for catheter related bloodstream infections," says CorMedix CEO, Joseph Todisco. "CorMedix remains committed to our goal of ensuring broad access to this important infection reduction mechanism."

Comments

Nippon Steel

Interés en corto

Nippon Steel (OTC:NPSCY) Bolsa, Informe de interés en corto

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL